



University of Groningen

## Molecular characterization of tumor vascular phenotype and pharmacology of antiangiogenic therapy

Langenkamp, Elise

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2010

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Langenkamp, E. (2010). Molecular characterization of tumor vascular phenotype and pharmacology of antiangiogenic therapy Groningen: s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Molecular characterization of tumor vascular phenotype and pharmacology of antiangiogenic therapy Printing of this thesis was financially supported by:



Mevr. G. Klein-Greeve, Wijhe ('Oma Geesje')

The cover illustrates a view on the inside of a tumor vessel: small molecule tyrosine kinase inhibitors in the bloodstream are finding their way to the tumor endothelium. Their effects on the tumor endothelium are molecularly characterized in this thesis.

Cover design: Maarten van Loon and Elise Langenkamp Lay-out: Elise Langenkamp Printed by: Off Page, Amsterdam ISBN: 978-90-367-4680-9 (printed version) ISBN: 978-90-367-4681-6 (digital version)

© 2010, Elise Langenkamp

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without permission of the author.



rijksuniversiteit groningen

# Molecular characterization of tumor vascular phenotype and pharmacology of antiangiogenic therapy

Proefschrift

ter verkrijging van het doctoraat in de Medische Wetenschappen aan de Rijksuniversiteit Groningen op gezag van de Rector Magnificus, dr. F. Zwarts, in het openbaar te verdedigen op woensdag 22 december 2010 om 14.45 uur

door

## Elise Langenkamp

geboren op 26 januari 1982 te Hoogeveen Promotor:

Prof. dr. G. Molema

Beoordelingscommissie:	Prof. dr. H.F. Dvorak, Harvard Medical School
	Prof. dr. A.S.H. Gouw
	Prof. dr. A.W. Griffioen, VU University Medical Center

Paranimfen:

Gesiena Elise van der Wal Neng Fisheri Kurniati

## CONTENTS

Introduction & Aim of the thesis	9
Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for antiangiogenic therapy of cancer <i>Cell Tissue Res. 2009 Jan;335(1):205-22</i>	21
Tumor vascular morphology undergoes dramatic changes during outgrowth of B16 melanoma, while pro-angiogenic gene expression remains unchanged <i>Submitted</i>	53
Angiogenic activation of endothelial cells impairs efficacy of VEGFR2 inhibitor treatment <i>in vitro Work in progress</i>	77
VEGFR2 inhibition in Lewis Lung Carcinoma induces vascular stabilization <i>in vivo</i> and concomitant loss of VEGFR2 protein <i>Submitted</i>	97
VEGFR2 inhibition <i>in vivo</i> affects tumor vasculature in a tumor type-dependent way, and downregulates VEGFR2 protein without a prominent role for microRNA-296 <i>Submitted</i>	121
Summary, discussion & future perspectives	143
Nederlandse samenvatting	165
Abbreviations Contributing authors Curriculum Vitae & List of publications Dankwoord	177 181 183 187
	<ul> <li>Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for antiangiogenic therapy of cancer</li> <li>Cell Tissue Res. 2009 Jan; 335(1):205-22</li> <li>Tumor vascular morphology undergoes dramatic changes during outgrowth of B16 melanoma, while pro-angiogenic gene expression remains unchanged</li> <li>Submitted</li> <li>Angiogenic activation of endothelial cells impairs efficacy of VEGFR2 inhibitor treatment <i>in vitro</i> Work <i>in progress</i></li> <li>VEGFR2 inhibition in Lewis Lung Carcinoma induces vascular stabilization <i>in vivo</i> and concomitant loss of VEGFR2 protein <i>Submitted</i></li> <li>VEGFR2 inhibition <i>in vivo</i> affects tumor vasculature in a tumor type-dependent way, and downregulates VEGFR2 protein without a prominent role for microRNA-296 Submitted</li> <li>Summary, discussion &amp; future perspectives</li> <li>Nederlandse samenvatting</li> <li>Abbreviations</li> <li>Contributing authors</li> </ul>